First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

NEXT STORY
DR. KAREN STEIN JOINS ABT AS LEAD SURVEY METHODOLOGIST
PREV STORY
Quotient Limited Announces receipt of Note Holders Consents to Indenture Amendments That Extend Maturity, Defer Principal Payments on 12% Senior Secured Notes
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS

author_avatar
NASDAQ Market News

Longeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

author_avatar
NASDAQ Market News

FDA grants Fast Track Designation for Celyad’s ischemic heart failure therapy, C-Cure®

Celyad intends to leverage this designation to accelerate the search for a strategic partnerDesignation ...

author_avatar
NASDAQ Market News